Yuancheng (Ryan) Lu, a geneticist at the Whitehead Institute in Cambridge, Massachusetts, has dedicated his career to tackling the challenges of aging, particularly in the realm of vision. His personal connection to age-related blindness—stemming from a family history that includes a great-aunt who tragically lost her life due to impaired eyesight—fuels his passion. Coupled with a genetic predisposition for macular degeneration, as revealed by a 23andMe test, Lu is driven to develop innovative gene therapies aimed at preventing vision loss associated with aging. “The eye is a really unique system to study aging and rejuvenation,” he notes, emphasizing its potential for scientific exploration.
Lu’s pioneering work in rejuvenation science gained significant attention with his 2018 PhD research at Harvard Medical School, where he employed a technique known as reprogramming to mend damaged optic nerves in mice. After intentionally damaging the nerves, he administered a gene therapy designed to restore youthful cellular functionality. Remarkably, just 16 days later, the optic nerves began to regenerate, showcasing visible signs of recovery under a microscope. This breakthrough led to further assessments, where the treated mice demonstrated the ability to see once again, a development heralded by longevity expert David Sinclair as a glimpse into the future.
This year marked a significant milestone as the genetic therapy, now known as ER-100, transitioned into human clinical trials. On June 9, Life Biosciences, a startup co-founded by Sinclair, announced the first injection of this treatment into a glaucoma patient. This event captured widespread media attention, with outlets like the New York Times suggesting the technology could alter the course of human health. Lu’s innovative approach, which refines the complex reprogramming process, focuses on a selective set of genes to mitigate potential risks. Despite the excitement surrounding age-reversal technologies, Lu remains grounded, recognizing the complexities of aging and the challenges that persist. His ongoing research endeavors aim to uncover additional rejuvenation therapies, with a particular focus on identifying protective genes that can combat age-related retinal damage. The dialogue around rejuvenation has evolved significantly over the past six years, and Lu’s contributions are pivotal in shaping this burgeoning field.
Source: This geneticist’s age-reversal tech could help restore sight via MIT Technology Review